Close
Smartlab Europe
Inizio Ignite

Ranbaxy Honored With Nabia Award For Excellence in New Jersey Business Expansion

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Addressing the Boomers: How Pharma Must Adapt Drug Development for the 65+ Demographic

An aging population is reshaping medicine. Why pharma must...

GCCL, Medicover Sign MOU for Clinical Trial Services Expansion

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services...

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...
- Advertisement -

Ranbaxy Inc., a research-based pharmaceutical company that manufactures generic product formulations, OTC and branded drug products, has been honored with the New Jersey Business Industry Association’s (NJBIA) Award for Excellence in Business Expansion and Economic Contribution to the State. 

The NJBIA award acknowledges Ranbaxy’s commitment and contribution to the State,  providing jobs for more than 700 New Jerseyans and with recent investments in its state-of-the-art manufacturing facilities in New Brunswick. NJBIA President Philip Kirschnerwill honor Ranbaxy and other recipients at an awards dinner on October 18, 2011 in Edison, NJ.

Ranbaxy entered the U.S. market in 1994 with a sales office in Raleigh, North Carolina.  It acquired Ohm Laboratories of North Brunswick, NJ, its first U.S. manufacturing facility in 1995 and subsequently relocated its North American headquarters to Princeton, NJ. Ohm Laboratories produces quality and affordable generic prescription product formulations, as well as OTC medications.

Latest stories

Related stories

Addressing the Boomers: How Pharma Must Adapt Drug Development for the 65+ Demographic

An aging population is reshaping medicine. Why pharma must...

GCCL, Medicover Sign MOU for Clinical Trial Services Expansion

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services...

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Bristol Myers Evinova Partnership Targets AI-Led Trials

Bristol Myers Squibb has entered a global agreement with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »